Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H11N3O.ClH |
| Molecular Weight | 201.653 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=NOC(=N1)[C@]23C[C@H]2CNC3
InChI
InChIKey=LFFMTVIROSODDO-QMGYSKNISA-N
InChI=1S/C8H11N3O.ClH/c1-5-10-7(12-11-5)8-2-6(8)3-9-4-8;/h6,9H,2-4H2,1H3;1H/t6-,8-;/m0./s1
| Molecular Formula | C8H11N3O |
| Molecular Weight | 165.1924 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 19:27:32 GMT 2025
by
admin
on
Wed Apr 02 19:27:32 GMT 2025
|
| Record UNII |
TH565G8BVK
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1364078-75-0
Created by
admin on Wed Apr 02 19:27:32 GMT 2025 , Edited by admin on Wed Apr 02 19:27:32 GMT 2025
|
PRIMARY | |||
|
TH565G8BVK
Created by
admin on Wed Apr 02 19:27:32 GMT 2025 , Edited by admin on Wed Apr 02 19:27:32 GMT 2025
|
PRIMARY | |||
|
165755512
Created by
admin on Wed Apr 02 19:27:32 GMT 2025 , Edited by admin on Wed Apr 02 19:27:32 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
The initial study to be conducted under this IND is Study ML-007-014, a hAME/mass balance
study, in which ML-007 mixed with a microtracer of [14C]-ML-007 will be coadministered with
fesoterodine as individual components in oral solution due to the nature of the clinical study.
|